Men and women aged 18-75 years old with a diagnosis of hidradenitis suppurativa (HS) and disease lasting for at least 6 months, may qualify to participate in this study. Individuals must have moderate to severe hidradenitis suppurativa with lesions in at least 2 distinct areas. A stable course of HS for at least 90 days before screening, will be determined by the study doctor.
Eligible participants will receive investigational oral medication (active drug or placebo). Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last up to 16 weeks and include about 8 visits to the study centre.
Email Tina Craig, Clincal Research Coordinator at DermEffects to register.